Thomas Friess

This inventor holds 13 USPTO granted patents and 33 published patent applications, plus 2 CIPO patents and 11 EPO patents, primarily in Antibody Therapeutics. Top assignees: Hoffmann-La Roche Inc., Roche Glycart Ag. Active years: 2006-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas Friess. Retrieved from https://idiyas.com/inventor/thomas-friess

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 33)

% Patents Active = 23.1

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 11 (Patent Applications = 16)

Average Co-Inventor Count = 6.0

ph-index = 3

Forward Citations = 38(Granted Patents)

Location History:

Planegg, DE (2006 - 2008)
Diessen-Dettenhofen, DE (2008 - 2019)
Diessen-Dettenhofen, GB (2019)

Company Filing History:

10 out of 5,035

Hoffmann-La Roche Inc.

Years Active: 2006-2019

Loading Chart...

Areas of Expertise:

Anti-TPBG Antibodies

Anti-HER3 Antibodies

Combination Therapy

Tumor Therapy

Vascular Endothelial Growth Factor

Human Epithelial Growth Factor Receptor

Ether Derivatives

Phenylpyridine Derivatives

Oxidized Thioether Derivatives

Indole Derivatives

Oxazole Derivatives

Benzylether Derivatives

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10434184 - Anti-TPBG antibodies and methods of use (2019-10-08),

2. 10196456 - Anti-HER3 antibodies and uses thereof (2019-02-05),

3. 9611331 - Anti-HER3 antibodies and uses thereof (2017-04-04),

4. 9180185 - Combination therapy of anti-HER3 antibodies (2015-11-10),

5. 9090700 - Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 (2015-07-28),

6. 8859737 - Anti-HER3 antibodies and uses thereof (2014-10-14),

7. 7432291 - Ether derivatives (2008-10-07),

8. 7429605 - Phenylpyridine derivatives (2008-09-30),

9. 7405231 - Oxidized thioether derivatives (2008-07-29),

10. 7342030 - Indole derivatives (2008-03-11),

11. 7205325 - Oxazole derivatives (2007-04-17),

12. 7163953 - Benzylether derivatives (2007-01-16),

13. 7005526 - Thioether derivatives (2006-02-28),

Title: Thomas Friess: Innovator in Antibody Development

Introduction

Thomas Friess is a prominent inventor based in Diessen-Dettenhofen, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. With a total of 13 patents to his name, Friess has established himself as a key figure in the industry.

Latest Patents

Among his latest patents are "Anti-TPBG antibodies and methods of use," which provides innovative anti-TPBG antibodies and methods for their application. Another notable patent is "Anti-HER3 antibodies and uses thereof," which relates to antibodies that bind to human HER3, detailing methods for their production, pharmaceutical compositions containing these antibodies, and their various uses.

Career Highlights

Throughout his career, Thomas Friess has worked with esteemed companies such as Hoffmann-La Roche Inc. and Roche Glycart AG. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field of antibodies.

Collaborations

Some of his notable coworkers include Birgit Bossenmaier and Edgar Voss. Their collaborative efforts have further advanced the research and applications of antibody technologies.

Conclusion

Thomas Friess is a distinguished inventor whose work in antibody development has had a profound impact on biotechnology. His innovative patents and collaborations continue to shape the future of medical research and treatment.

Profile summary based on public USPTO records.